Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Safety Run-in Study and Phase 1b Randomized, Double Blinded, Placebo Controlled Trial

Next Previous
X
Search
Trial Profile

Phase 1 Safety Run-in Study and Phase 1b Randomized, Double Blinded, Placebo Controlled Trial

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CK 0803 (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms REGALS
  • Sponsors Cellenkos

    • Most Recent Events

    • 19 Feb 2024 According to a Cellenkos media release, the company got approval from the Data Safety Monitoring Board (DSMB) for CK0803 neurotrophic T regulatory (Treg) cell therapy,to proceed with the second group of patients in the trial
    • 19 Jan 2024 According to a Cellenkos media release, Dr. James Orengo is principal investigator of this study.
    • 19 Jan 2024 According to a Cellenkos media release, the first cohort of phase 1/1b CK0803 trial has been completed and is currently open for enrollment at Columbia University, New York, NY, led by PI, Dr Neil Shneider, M.D., Ph.D., director of Columbia Universitys Eleanor and Lou Gehrig ALS Center.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top